Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJocelyn Holash, Jesse M. Cedarbaum, John Rudge, George D. Yancopoulos, Neil Stahl
Life of this patent
Estimating the term…
Abstract
Methods of treating anemic disorders in human subjects comprising administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component. Further included are methods of preventing anemia, increasing hematocrit levels, and increasing or stimulating erythropoietin, particularly in subjects being treated for cancer with chemotherapeutic agents and/or radiation.
Claims12
A method of treating an anemic disorder in a human subject in need thereof, comprising administering to the human subject a vascular endothelial growth factor (VEGF) antagonist capable of blocking, inhibiting, or ameliorating VEGF-mediated activity, wherein the VEGF antagonist is fusion polypeptide VEGRF1R2-FcΔC1(a) (SEQ ID NO:4).
A method of treating anemia expected to result from cancer treatment in a human subject at risk, comprising administering to the human subject fusion polypeptide VEGRF1R2-FcΔC1(a) (SEQ ID NO:4).
A method of increasing hematocrit level in a human subject in need thereof, comprising administering to the human subject a vascular endothelial growth factor (VEGF) antagonist comprising fusion polypeptide VEGRF1R2-FcΔC1(a) (SEQ ID NO:4).
A method of increasing erythropoietin levels in a human subject in need thereof, comprising administering to the human subject a vascular endothelial growth factor (VEGF) antagonist comprising fusion polypeptide VEGRF1R2-FcΔC1(a) (SEQ ID NO:4).
A method of stimulating erythropoiesis in a human subject in need thereof, comprising administering to the human subject a vascular endothelial growth factor (VEGF) antagonist comprising fusion polypeptide VEGRF1R2-FcΔC1(a) (SEQ ID NO:4).
Dependencies are inferred from the claim text.